Prenatal screening for thrombophilias: Indications and controversies

Clinics in Laboratory Medicine

Volumn 30, Issue 3, 2010, Pages 747-760

  Carbone, Jeanine F ^a   Rampersad, Roxane ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired thrombophilia; Inherited thrombophilia; Pregnancy; Thromboembolism; Thrombophilia; Venous

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; CYANOCOBALAMIN; FOLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PLACEBO; PROTEIN S; PROTHROMBIN; PYRIDOXINE; WARFARIN;

ADVERSE OUTCOME; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; CLINICAL DECISION MAKING; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; FETUS WASTAGE; GENE MUTATION; GENETIC SCREENING; HIGH RISK PREGNANCY; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; MATERNAL DISEASE; MEDICAL HISTORY; PREECLAMPSIA; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SOLUTIO PLACENTAE; THROMBOPHILIA; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; COMPLICATION; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL DIAGNOSIS;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PRENATAL DIAGNOSIS; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 77954769441     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2010.05.003     Document Type: Review

References (71)

1. Brenner B. Thrombophilia and adverse pregnancy outcome. Obstet Gynecol Clin North Am 2006, 33(3):443-456. ix.
2. Barbour L.A. ACOG educational bulletin. Thromboembolism in pregnancy. Number 234, March 1997. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1997, 57(2):209-218.
3. Creasy R.K., Resnik R., Iams J.D. Creasy and Resnik's maternal-fetal medicine: principles and practice 2009, Saunders/Elsevier, Philadelphia. 6th edition.
4. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003, 29(2):125-130.
5. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001, 114(3):512-528.
6. Marik P.E., Plante L.A. Venous thromboembolic disease and pregnancy. N Engl J Med 2008, 359(19):2025-2033.
7. Greer I.A. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999, 353(9160):1258-1265.
8. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 1999, 353(9159):1167-1173.
9. Lockwood C.J. Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol 2002, 99(2):333-341.
10. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000, 342(6):374-380.
11. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88(10):3698-3703.
12. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983, 62(3):239-243.
13. Girling J., de Swiet M. Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998, 10(2):135-144.
14. Lane D.A., Bayston T., Olds R.J., et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997, 77(1):197-211.
15. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10(1):111-113.
16. Morelli V.M., Lourenco D.M., D'Almeida V., et al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677 T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis 2002, 13(3):271-275.
17. Miletich J., Sherman L., Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987, 317(16):991-996.
18. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995, 73(1):87-93.
19. Foster D.C., Yoshitake S., Davie E.W. The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci U S A 1985, 82(14):4673-4677.
20. Plutzky J., Hoskins J.A., Long G.L., et al. Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A 1986, 83(3):546-550.
21. Clouse L.H., Comp P.C. The regulation of hemostasis: the protein C system. N Engl J Med 1986, 314(20):1298-1304.
22. Dykes A.C., Walker I.D., McMahon A.D., et al. A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001, 113(3):636-641.
23. Ploos van Amstel J.K., van der Zanden A.L., Bakker E., et al. Two genes homologous with human protein S cDNA are located on chromosome 3. Thromb Haemost 1987, 58(4):982-987.
24. Schmidel D.K., Tatro A.V., Phelps L.G., et al. Organization of the human protein S genes. Biochemistry 1990, 29(34):7845-7852.
25. Esmon C.T. The protein C anticoagulant pathway. Arterioscler Thromb 1992, 12(2):135-145.
26. Schwarz H.P., Fischer M., Hopmeier P., et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984, 64(6):1297-1300.
27. Broekmans A.W., Bertina R.M., Reinalda-Poot J., et al. Hereditary protein S deficiency and venous thrombo-embolism. A study in three Dutch families. Thromb Haemost 1985, 53(2):273-277.
28. Holmes Z.R., Bertina R.M., Reitsma P.H. Characterization of a large chromosomal deletion in the PROS1 gene of a patient with protein S deficiency type I using long PCR. Br J Haematol 1996, 92(4):986-991.
29. Zoller B., Berntsdotter A., Garcia de Frutos P., et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995, 85(12):3518-3523.
30. MacCallum P.K., Cooper J.A., Martin J., et al. Associations of protein C and protein S with serum lipid concentrations. Br J Haematol 1998, 102(2):609-615.
31. Esplin S.M. ACOG Practice Bulletin #68: antiphospholipid syndrome. Obstet Gynecol 2005, 106(5 Pt 1):1113-1121.
32. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4(2):295-306.
33. Passam F., Krilis S. Laboratory tests for the Antiphospholipid syndrome: current concepts. Pathology 2004, 36(2):129-138.
34. Roubey R.A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other " antiphospholipid" autoantibodies. Blood 1994, 84(9):2854-2867.
35. Heit J.A., Kobbervig C.E., James A.H., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005, 143(10):697-706.
36. James A.H., Jamison M.G., Brancazio L.R., et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194(5):1311-1315.
37. Eby C. Antiphospholipid syndrome review. Clin Lab Med 2009, 29(2):305-319.
38. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46(4):1019-1027.
39. Silver R.M., Draper M.L., Scott J.R., et al. Clinical consequences of antiphospholipid antibodies: an historic cohort study. Obstet Gynecol 1994, 83(3):372-377.
40. Zotz R.B., Gerhardt A., Scharf R.E. Inherited thrombophilia and gestational venous thromboembolism. Best Pract Res Clin Haematol 2003, 16(2):243-259.
41. Seligsohn U., Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001, 344(16):1222-1231.
42. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006, 132(2):171-196.
43. Kang S.S., Zhou J., Wong P.W., et al. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988, 43(4):414-421.
44. Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005, 3(2):292-299.
45. McColl M.D., Ellison J., Reid F., et al. Prothrombin 20210 G->A, MTHFR C677 T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000, 107(4):565-569.
46. Domagala T.B., Adamek L., Nizankowska E., et al. Mutations C677 T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002, 13(5):423-431.
47. den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007, 109(1):139-144.
48. Friederich P.W., Sanson B.J., Simioni P., et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996, 125(12):955-960.
49. Vila P., Hernandez M.C., Lopez-Fernandez M.F., et al. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994, 72(2):209-213.
50. Oshiro B.T., Silver R.M., Scott J.R., et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996, 87(4):489-493.
51. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314(7076):253-257.
52. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174(5):1584-1589.
53. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100(3):408-413.
54. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002, 101(1):6-14.
55. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003, 361(9361):901-908.
56. Kovalevsky G., Gracia C.R., Berlin J.A., et al. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004, 164(5):558-563.
57. Lissalde-Lavigne G., Fabbro-Peray P., Cochery-Nouvellon E., et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005, 3(10):2178-2184.
58. Roque H., Paidas M.J., Funai E.F., et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004, 91(2):290-295.
59. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004, 103(10):3695-3699.
60. Branch D.W., Silver R.M., Blackwell J.L., et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992, 80(4):614-620.
61. Lima F., Khamashta M.A., Buchanan N.M., et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996, 14(2):131-136.
62. Yasuda M., Takakuwa K., Tokunaga A., et al. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstet Gynecol 1995, 86(4 Pt 1):555-559.
63. Lynch A., Marlar R., Murphy J., et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994, 120(6):470-475.
64. Pattison N.S., Chamley L.W., McKay E.J., et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynaecol 1993, 100(10):909-913.
65. Facco F., You W., Grobman W. Genetic thrombophilias and intrauterine growth restriction: a meta-analysis. Obstet Gynecol 2009, 113(6):1206-1216.
66. Fretts R.C. ACOG Practice Bulletin No. 102: Management of stillbirth. Obstet Gynecol 2009, 113(3):748-761.
67. James A.H. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007, 120(10 Suppl 2):S26-S34.
68. Ginsberg J.S., Kowalchuk G., Hirsh J., et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989, 149(10):2233-2236.
69. Lepercq J., Conard J., Borel-Derlon A., et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001, 108(11):1134-1140.
70. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000, 343(20):1439-1444.
71. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(6 Suppl):844S-886S.